PET-guided radiation for metastatic hormone-sensitive prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether using a special PET scan (FDG-PET) to find and treat only the spots where cancer has spread with targeted radiation can help men with prostate cancer that has spread but still responds to hormone therapy. It compares standard treatment alone to standard treatment plus this targeted radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of the body, seen on a CT, MRI, or bone scan.
- You are at least 18 years old.
- You have a performance status of 0 to 3 (you are up and about at least half the day).
- You are starting or have recently started hormone therapy, with or without chemotherapy or other hormone-blocking drugs.
- You can lie still for about 15-20 minutes and tolerate PET scans and radiation planning.
- You have adequate blood cell counts (white blood cells, neutrophils, and platelets).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
Hear when a new Castration-Sensitive Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.